Raymond James Financial Inc. Makes New Investment in Genelux Co. (NASDAQ:GNLX)

Raymond James Financial Inc. bought a new position in Genelux Co. (NASDAQ:GNLX) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 17,250 shares of the company’s stock, valued at approximately $41,000.

Several other hedge funds also recently bought and sold shares of GNLX. Apollon Wealth Management LLC raised its holdings in shares of Genelux by 20.4% during the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock worth $40,000 after acquiring an additional 2,857 shares during the period. D.A. Davidson & CO. acquired a new stake in shares of Genelux during the fourth quarter worth $51,000. LPL Financial LLC raised its holdings in shares of Genelux by 72.3% during the fourth quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock worth $222,000 after acquiring an additional 39,516 shares during the period. LifeSteps Financial Inc. raised its holdings in shares of Genelux by 11.1% during the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock worth $205,000 after acquiring an additional 8,715 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Genelux during the fourth quarter worth $25,000. 37.33% of the stock is currently owned by institutional investors and hedge funds.

Genelux Trading Down 3.2%

Shares of GNLX stock opened at $2.40 on Thursday. Genelux Co. has a 1 year low of $1.60 and a 1 year high of $5.89. The firm’s fifty day moving average price is $2.88 and its two-hundred day moving average price is $3.11. The firm has a market capitalization of $90.56 million, a P/E ratio of -2.53 and a beta of -0.33.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.03. As a group, equities research analysts forecast that Genelux Co. will post -0.88 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Genelux in a report on Monday, March 31st. Benchmark dropped their price objective on shares of Genelux from $25.00 to $23.00 and set a “speculative buy” rating on the stock in a report on Thursday, May 8th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $17.75.

Genelux Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.